Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorPusan National University Yangsan Hospital
About this trial
Remimazolam is a medication that has the advantage of a short half-life and reversibility with flumazenil. In clinical situations, the use of flumazenil for the reversal of sedation is common, but there is no precise indication for its administration. In this study, we aim to investigate the necessity of routine flumazenil use after administering remimazolam for intravenous anesthesia.
Eligibility criteria
Qualifiers
Patients over 65 years old scheduled for hip joint surgery
Disqualifiers
Patients with impaired consciousness or delirium before surgery
Patients who are hemodynamically unstable before surgery
Patients with a history of neurological or neuromuscular disorders or use of medications that affect neurological or neuromuscular function
Patients who have taken sedatives (anti-anxiety medications, antipsychotics, antidepressants, sleep aids) within the past 24 hours
Trial design
Treatments tested in this trial
- Flumazenil
- normal saline
Treatment groups
24 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov